1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
SunMax Biotechnology Co. Ltd.

SunMax Biotechnology Co. Ltd.

TTPEX:4728
395.50
TWD
+1.50
(+0.38%)
14.88EPS
25.41P/E
20.61BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.92
3.38
2.06
2.88
3.52
5.61
10.91
15.71
19.02
25.71
31.01
33.38
37.2
40.29
Basic EPS, GAAP
0.88
0.37
-0.81
0.03
0.31
1.38
1.84
4.37
4.51
9.8
11.49
12.47
13.33
14.9
Free Cash Flow per Basic Share
0.92
0.5
-0.49
0.22
0.62
1.77
5.06
4.72
-0.22
8.99
13.55
9.62
13.91
15.82
Dividend per Share
0.5
0.6
0.6
- -
- -
0.3
1.2
1.5
2
4.4
9.5
11
11.6
- -
Book Value per Share
12.09
11.9
10.25
10.28
10.6
11.9
12.43
16.32
18.79
24.33
26.18
27.78
29.7
26.27
Tangible Book Value per Share
11.5
11.4
9.83
9.96
10.35
11.72
12.27
16.22
18.72
24.26
26.09
27.66
29.52
26.13
Basic Weighted Avg Shares
54
54
54
54
54
54
54
54
54
54
54
54
54
54
Sales/Revenue/Turnover
213
184
112
156
190
304
594
856
1,036
1,400
1,689
1,818
2,026
2,195
Operating Margin (%)
21.84
6.73
-43.97
1.99
6.98
21.02
29.88
38.55
35.5
54.83
52.98
50.99
49.27
49.82
Depreciation Expense
9
9
10
10
9
7
14
34
56
58
73
99
102
113
Net Income, GAAP
48
20
-44
2
17
75
100
238
246
534
626
679
726
812
Effective Tax Rate (%)
7.14
34.2
- -
57.79
22.04
14.56
34.95
29.51
31.29
31.31
31.19
28.73
28.47
27.51
Profit Margin (%)
22.56
11.01
-39.55
1.12
8.7
24.55
16.91
27.82
23.72
38.13
37.05
37.37
35.82
36.97
Working Capital
543
544
462
467
466
508
550
671
454
580
622
764
849
627
LT Debt
- -
- -
- -
- -
24
- -
110
105
67
50
145
122
94
74
Total Equity
670
659
558
555
573
648
677
889
1,024
1,325
1,426
1,513
1,618
1,431
Return on Invested Capital (%)
6.54
1.22
- -
0.12
1.79
8.36
15.06
24.91
22.25
39.27
38.69
38.55
40.28
50.12
Return on Capital (%)
7.33
3.09
- -
0.31
2.86
11.8
13.88
26.34
22.95
42.3
41.91
41.96
42.96
55.95
Return on Common Equity (%)
7.45
3.1
-7.32
0.31
2.93
12.23
15.16
30.41
25.69
45.45
45.48
46.24
46.36
60.67

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
25
34
34
LT Borrowings
- -
- -
- -
LT Finance Leases
94
82
74
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
21,567
20,887
20,614

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,143
1,395
1,031
Cash, Cash Equivalents & STI
962
1,197
793
Accounts Receivable, Net
1
1
2
Inventories
153
172
192
Total Current Liabilities
294
1,045
404
Payables & Accruals
- -
- -
- -
ST Debt
25
34
34
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.68%
13.05%
6.94%
Free Cash Flow
-376.25%
-833.59%
44.57%
Net Income, GAAP
142.03%
30.62%
6.82%
Sales/Revenue/Turnover
35.68%
19.19%
11.45%
Total Cash Common Dividend
- -
58.1%
5.45%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
428
454
458
479
1,818
2025
554
460
504
508
2,026
2026
565
618
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.24
3.35
3.15
2.74
12.47
2025
4.1
2.84
3.48
2.9
13.33
2026
4.07
4.45
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
11
2025
- -
- -
- -
- -
11.6
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chi Kuo Lin
Full Time Employees
30
Sector
Health technology
Industry
Medical specialties
Address
No. 10, Lane 31, Huandong Road Tainan TQ Taiwan 744
IPO Date
Jan 25, 2010
Website
sunmaxbiotech.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Sunmax Biotechnology Co., Ltd. (4728.TWO) develops, manufactures, and markets collagen-based medical devices and bio-surgical products primarily in Taiwan and Mainland China. The company offers dermal fillers including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sunmax collagen implant I, and Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for wrinkle correction and facial defect treatment; Porcogen, a sterile purified collagen solution for medical devices, tissue engineering, and research; dental products such as Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules for alveolar ridge augmentation; orthopedic solutions like Sunmax collagen bone graft matrix as a resorbable bone void filler; and skincare items comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare for post-dermal filler aftercare. Founded in 2001 and headquartered in Tainan City, Taiwan, at No. 10, Lane 31, Section 1, Huandong Road, Xinshi District, Sunmax Biotechnology serves healthcare providers, dental professionals, and cosmetic markets with biomedical-grade collagen applications across medical aesthetics, dentistry, orthopedics, and consumer skincare. The company became a subsidiary of The Ginko International Group in 2016, maintains the only collagen implant license in China following its 2013 CFDA approval for Collagen Implant 1, and holds breakthroughs like a 2014 triple cross-linked collagen patent authorized in the USA, China, and Taiwan alongside ongoing expansions in international certifications and distribution.